Nevertheless, elevated levels of VEGF in serum and plasma in comparison to non-cancer control groups have been detected throughout studies [13,14,15] and thereby highlight that VEGF should be considered more for investigations, especially in regards to actual studies and the development of anti-angiogenetic drugs targeting for instance VEGF and its receptors in HNSCC. This evidence concerns the gene VEGFA and head and neck squamous cell carcinoma.